BioCentury on BioBusiness,
Low-key path to the buy-out
Monday, December 23, 1996
American Home Products Corp. surprised the world last week when it
exercised its option to buy the 40 percent of Genetics Institute Inc. it didn't already
own for $1 billion net of cash. Unlike the period leading up to the expiration of Roche's
option to purchase the remainder of Genentech Inc., the months leading up to AHP's option
deadline were relatively quiet and free of speculation. Indeed, the $85 buyout price
represented a 38 percent premium to the market on the day of the announcement. And
unlike GNE, which put some effort into raising its stock price to levels that would make
the buyout attractive, GENIZ was content to let matters take their own course.
BioCentury talked to Gabriel Schmergel, GENIZ's retiring president and
CEO, about the company's philosophy and its relationship with AHP, which acquired a 60
percent stake in 1992.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]